[go: up one dir, main page]

WO2025008516A3 - Nouveaux composés - Google Patents

Nouveaux composés Download PDF

Info

Publication number
WO2025008516A3
WO2025008516A3 PCT/EP2024/069024 EP2024069024W WO2025008516A3 WO 2025008516 A3 WO2025008516 A3 WO 2025008516A3 EP 2024069024 W EP2024069024 W EP 2024069024W WO 2025008516 A3 WO2025008516 A3 WO 2025008516A3
Authority
WO
WIPO (PCT)
Prior art keywords
factor
inhibitory activity
indole derivatives
compounds
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/069024
Other languages
English (en)
Other versions
WO2025008516A2 (fr
Inventor
John Andrew Christopher
Paul Graham Wyatt
Thomas William HORNSBY
Martin Edward Cooper
Mark Mills
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sitala Bio Ltd
Original Assignee
Sitala Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2316974.1A external-priority patent/GB202316974D0/en
Application filed by Sitala Bio Ltd filed Critical Sitala Bio Ltd
Publication of WO2025008516A2 publication Critical patent/WO2025008516A2/fr
Publication of WO2025008516A3 publication Critical patent/WO2025008516A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des esters actifs d'inhibiteurs du facteur B, ainsi que des sels, des solvates, des promédicaments et des compositions pharmaceutiques associés. La présente invention concerne en outre des procédés de synthèse de tels composés, et l'utilisation de tels composés dans le traitement et la prévention de troubles et de troubles médicaux, plus particulièrement par inhibition du facteur B.
PCT/EP2024/069024 2023-07-06 2024-07-05 Nouveaux composés Pending WO2025008516A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB202310422 2023-07-06
GB2310422.7 2023-07-06
GB2316974.1 2023-11-06
GBGB2316974.1A GB202316974D0 (en) 2023-11-06 2023-11-06 Novel compounds

Publications (2)

Publication Number Publication Date
WO2025008516A2 WO2025008516A2 (fr) 2025-01-09
WO2025008516A3 true WO2025008516A3 (fr) 2025-02-13

Family

ID=91899194

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/069024 Pending WO2025008516A2 (fr) 2023-07-06 2024-07-05 Nouveaux composés

Country Status (1)

Country Link
WO (1) WO2025008516A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025172535A1 (fr) 2024-02-15 2025-08-21 Sitala Bio Ltd Composés indole et benzimidazole utilisés en tant qu'inhibiteurs du facteur b

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015009616A1 (fr) * 2013-07-15 2015-01-22 Novartis Ag Dérivés de pipéridinyl-indole et leur utilisation en tant qu'inhibiteurs du facteur b du complément

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027113B1 (ru) 2012-05-04 2017-06-30 Новартис Аг Регуляторы пути комплемента и их применение
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
CN105229003B (zh) 2013-03-14 2017-03-15 诺华股份有限公司 作为补体因子b抑制剂用于治疗眼科疾病的2‑(1h‑吲哚‑4‑基甲基)‑3h‑咪唑并[4,5‑b]吡啶‑6‑甲腈衍生物
CN114057692B (zh) 2020-08-07 2023-07-21 上海美悦生物科技发展有限公司 一种杂环类化合物、其制备方法及用途
IL300432A (en) 2020-08-07 2023-04-01 Shanghai Meiyue Biotech Dev Co Ltd An inhibitor of complement factor B, and the composition of the drugs, the method of preparation therefor and its use
KR20230128039A (ko) 2020-12-30 2023-09-01 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 질소-함유 가교 헤테로사이클릭 화합물, 그의 제조방법 및 그의 의학적 용도
CA3203447A1 (fr) 2020-12-30 2022-07-07 Kevin X Chen Serie de composes d'acide benzoique substitues par piperidine et leur utilisation
CA3205097A1 (fr) 2021-01-14 2022-07-21 Jason Allan Wiles Inhibiteurs macrocycliques du facteur b du complement
US20240217953A1 (en) 2021-04-16 2024-07-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bicyclic substituted aromatic carboxylic acid compounds
PE20250114A1 (es) 2021-06-03 2025-01-16 Chinook Therapeutics Inc Compuestos indol sustituidos y metodos de uso de los mismos
US20240360103A1 (en) 2021-06-30 2024-10-31 Apellis Pharmaceuticals, Inc. Complement inhibition
JP2024532847A (ja) 2021-08-18 2024-09-10 シーザン ハイスーク ファーマシューティカル カンパニー リミテッド ベンズアゼピン芳香環誘導体及びその医薬的な応用
MX2024004921A (es) 2021-10-27 2024-06-19 Hansoh Bio Llc Derivados de piperidinilindol, metodos de preparacion y usos medicinales de estos.
IL314186A (en) 2022-01-24 2024-09-01 Novartis Ag Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof
US20250223277A1 (en) 2022-04-01 2025-07-10 Novartis Ag Complement factor b inhibitors and uses thereof
WO2024049977A1 (fr) 2022-08-31 2024-03-07 Chinook Therapeutics, Inc. Composés d'indole substitués et leurs procédés d'utilisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015009616A1 (fr) * 2013-07-15 2015-01-22 Novartis Ag Dérivés de pipéridinyl-indole et leur utilisation en tant qu'inhibiteurs du facteur b du complément

Also Published As

Publication number Publication date
WO2025008516A2 (fr) 2025-01-09

Similar Documents

Publication Publication Date Title
CR20230310A (es) Inhibidores de prmt5
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MY210283A (en) 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
MX2021004431A (es) Procesos novedosos.
MX2024007058A (es) Derivados de 5,6,7,8-tetrahidro-2,6-naftiridina como terapeuticos contra el cancer.
WO2019195720A8 (fr) Benzofurane, benzopyrrole, benzothiophène substitués et inhibiteurs du complément structurellement apparentés
MX2022013482A (es) Compuestos utiles para inhibir la quinasa ret.
WO2021168483A3 (fr) Traitement d'infections à coronavirus humain à l'aide d'inhibiteurs de traitement de glycoprotéine alpha-glucosidase
PH12021552930A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
MX2025005941A (es) Moduladores de la actividad tnf-\03b1
PH12022550790A1 (en) Oral complement factor d inhibitors
TN2022000255A1 (en) Pyrrolopyrimidine amines as complement inhibitors
WO2021232067A8 (fr) Inhibition de stats3 pour le traitement et la prévention d'une infection à coronavirus humain
PH12022552727A1 (en) COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2a AND THEIR METHODS OF USE
WO2022268935A3 (fr) Nouveau procédé
WO2025008516A3 (fr) Nouveaux composés
WO2024189598A3 (fr) Inhibiteurs de kat6a de type acylsulfonamides
TN2022000095A1 (en) Oral complement factor d inhibitors
MX2025001865A (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
MX2023007150A (es) Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos.
WO2021242844A8 (fr) Inhibiteurs de grk2 et leurs utilisations
WO2024026481A3 (fr) Inhibiteurs de cdk2 et leurs procédés d'utilisation
WO2024026484A3 (fr) Inhibiteurs de cdk2 et leurs procédés d'utilisation
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
WO2017029588A3 (fr) Associations pharmaceutiques et leur utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24740851

Country of ref document: EP

Kind code of ref document: A2